Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00161-17. doi: 10.1128/AAC.00161-17. Print 2017 Aug.

Differential Activity of the Oral Glucan Synthase Inhibitor SCY-078 against Wild-Type and Echinocandin-Resistant Strains of Candida Species.

Author information

1
JMI Laboratories, North Liberty, Iowa, USA.
2
Scynexis, Inc., Jersey City, New Jersey, USA.
3
JMI Laboratories, North Liberty, Iowa, USA mariana-castanheira@jmilabs.com.

Abstract

SCY-078 (formerly MK-3118) is a novel orally active inhibitor of fungal β-(1,3)-glucan synthase (GS). SCY-078 is a derivative of enfumafungin and is structurally distinct from the echinocandin class of antifungal agents. We evaluated the in vitro activity of this compound against wild-type (WT) and echinocandin-resistant isolates containing mutations in the FKS genes of Candida spp. Against 36 Candida spp. FKS mutants tested, 30 (83.3%) were non-WT to 1 or more echinocandins, and only 9 (25.0%) were non-WT (MIC, >WT-upper limit) to SCY-078. Among C. glabrata isolates carrying FKS alterations, 84.0% were non-WT to the echinocandins versus only 24.0% for SCY-078. In contrast to the echinocandin comparators, the activity of SCY-078 was minimally affected by the presence of FKS mutations, suggesting that this agent is useful in the treatment of Candida infections due to echinocandin-resistant strains.

KEYWORDS:

Candida; SCY; antifungal susceptibility testing; echinocandin resistance

PMID:
28533234
PMCID:
PMC5527608
DOI:
10.1128/AAC.00161-17
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center